Multimarker Assessment of B-Cell and Plasma Cell Subsets and Their Prognostic Role in the Colorectal Cancer Microenvironment.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published Date:

Abstract

PURPOSE: Although the association between cytotoxic T lymphocytes and favorable prognosis in colorectal cancer is well established, the prognostic significance of B lymphocytes remains more ambiguous. This study aimed to assess the characteristics and significance of various B-cell and plasma cell subsets in colorectal tumors.

Authors

  • Onni Sirkiä
    Department of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
  • Henna Karjalainen
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Hanna Elomaa
    Department of Education and Research, Well Being Services County of Central Finland, Jyväskylä, Finland.
  • Sara A Väyrynen
    Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Anne Tuomisto
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Päivi Sirniö
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Ville K Äijälä
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Vilja V Tapiainen
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Meeri Kastinen
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Erkki-Ville Wirta
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
  • Olli Helminen
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Sanna Meriläinen
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Jukka Rintala
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Juha Saarnio
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Tero Rautio
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Toni T Seppälä
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
  • Markus J Mäkinen
    Translational Medicine Research Unit, University of Oulu, Medical Research Center Oulu, and Oulu University Hospital, Oulu, Finland.
  • Jukka-Pekka Mecklin
    Department of Education and Research, Well Being Services County of Central Finland, Jyväskylä, Finland.
  • Jan Böhm
    Department of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
  • Maarit Ahtiainen
    Central Finland Biobank, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
  • Juha P Väyrynen
    Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.